CRMD CorMedix Inc

USD 4.16 0.05 1.216545
Icon

CorMedix Inc (CRMD) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Very Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 4.16

+0.05 (+1.22)%

USD 0.21B

0.38M

USD 13.63(+227.52%)

N/A

Icon

CRMD

CorMedix Inc (USD)
COMMON STOCK | NSD
USD 4.16
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Very Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 0.21B

N/A

USD 4.16

CorMedix Inc (CRMD) Stock Forecast

Show ratings and price targets of :
USD 13.63
(+227.52%)

Based on the CorMedix Inc stock forecast from 4 analysts, the average analyst target price for CorMedix Inc is USD 13.63 over the next 12 months. CorMedix Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of CorMedix Inc is Very Bearish, which is based on 0 positive signals and 3 negative signals. At the last closing, CorMedix Inc’s stock price was USD 4.16. CorMedix Inc’s stock price has changed by +9.47% over the past week, +17.85% over the past month and +20.93% over the last year.

No recent analyst target price found for CorMedix Inc
No recent average analyst rating found for CorMedix Inc

Company Overview CorMedix Inc

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath and Neutrolin, a n...Read More

https://www.cormedix.com

300 Connell Drive, Berkeley Heights, NJ, United States, 07922

0

December

USD

USA

Adjusted Closing Price for CorMedix Inc (CRMD)

Loading...

Unadjusted Closing Price for CorMedix Inc (CRMD)

Loading...

Share Trading Volume for CorMedix Inc Shares

Loading...

Compare Performance of CorMedix Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for CRMD

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To CorMedix Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVO
Novo Nordisk A/S -1.36 (-1.05%) USD554.45B 46.01 4.80

ETFs Containing CRMD

Symbol Name CRMD's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About CorMedix Inc (CRMD) Stock

Based on ratings from 4 analysts CorMedix Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 8 buy, sell and hold ratings.

Unfortunately we do not have enough data on CRMD's stock to indicate if its a good dividend stock.

Based on targets from 4 analysts, the average taret price for CRMD is USD 13.63 over the next 12 months. The maximum analyst target price is USD 19 while the minimum anlayst target price is USD 9.

Unfortunately we do not have enough data on CRMD's stock to indicate if its overvalued.

The last closing price of CRMD's stock was USD 4.16.

The most recent market capitalization for CRMD is USD 0.21B.

Based on targets from 4 analysts, the average taret price for CRMD is projected at USD 13.63 over the next 12 months. This means that CRMD's stock price may go up by +227.52% over the next 12 months.

We can't find any ETFs which contains CorMedix Inc's stock.

As per our most recent records CorMedix Inc has 0 Employees.

CorMedix Inc's registered address is 300 Connell Drive, Berkeley Heights, NJ, United States, 07922. You can get more information about it from CorMedix Inc's website at https://www.cormedix.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...